PMID- 19660589
OWN - NLM
STAT- MEDLINE
DCOM- 20091021
LR  - 20090914
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 27
IP  - 42
DP  - 2009 Sep 25
TI  - Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent 
      Ag-specific and anti-tumour immunity.
PG  - 5846-54
LID - 10.1016/j.vaccine.2009.07.053 [doi]
AB  - High-mobility group box 1 (HMGB1) protein is a nuclear binding protein which is 
      released by monocytes and macrophages and is a potent maturation signal for 
      dendritic cells (DCs). Synthetic HMGB1-related peptides are reported to be potent 
      DC stimulants. Two HMGB1-related peptides, denoted as pHMGB-89 and pHMGB-106, 
      were explored for their ability to enhance the immunogenicity of Ag-containing 
      liposomes. pHMGB-engrafted liposomes targeted murine CD11c(+) and CD11b(+) cells 
      in vitro and in vivo. Vaccination of mice with OVA-containing liposomes engrafted 
      with pHMGB-89 and pHMGB-106 induced OVA-specific T cell priming and production of 
      IgG(1), IgG(2a) and IgG(2b) antibodies. Importantly, vaccination of mice with 
      B16-OVA-derived plasma membrane vesicles (PMVs) engrafted with pHMGB-89 and 
      pHMGB-106 inhibited tumour growth and metastasis, in syngeneic mice challenged 
      with highly metastatic B16-OVA melanoma. The results show that vaccination with 
      Ag-containing liposomes/PMVs engrafted with HMGB1 peptides could be an effective 
      approach for developing novel vaccines and cancer immunotherapies.
FAU - Faham, Abdus
AU  - Faham A
AD  - Biochemistry and Molecular Biology, Research School of Biology, ANU College of 
      Medicine, Biology and Environment, The Australian National University, Canberra, 
      ACT, 0200, Australia.
FAU - Bennett, David
AU  - Bennett D
FAU - Altin, Joseph G
AU  - Altin JG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090804
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HMGB1 Protein)
RN  - 0 (Liposomes)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antibodies, Neoplasm/blood/immunology
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - HMGB1 Protein/*immunology
MH  - Interferon-gamma/immunology
MH  - Liposomes/*immunology
MH  - Lymphocyte Activation
MH  - Melanoma, Experimental/immunology/prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Spleen/cytology/immunology
EDAT- 2009/08/08 09:00
MHDA- 2009/10/22 06:00
CRDT- 2009/08/08 09:00
PHST- 2009/05/15 00:00 [received]
PHST- 2009/07/13 00:00 [revised]
PHST- 2009/07/18 00:00 [accepted]
PHST- 2009/08/08 09:00 [entrez]
PHST- 2009/08/08 09:00 [pubmed]
PHST- 2009/10/22 06:00 [medline]
AID - S0264-410X(09)01085-8 [pii]
AID - 10.1016/j.vaccine.2009.07.053 [doi]
PST - ppublish
SO  - Vaccine. 2009 Sep 25;27(42):5846-54. doi: 10.1016/j.vaccine.2009.07.053. Epub 
      2009 Aug 4.